HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
• Treatments: Cytarabine; Idarubicin; Lenograstim

Criteria

Inclusion Criteria:

1. Having signed informed consent

2. Diagnosis was based on the French-American-British (FAB) and WHO criteria.

3. Age ≥ 7 years old

4. Age < 60 years old

Exclusion Criteria:

1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia